Acute plasma amylase increase after glucagon-like peptide-1 receptor agonist exenatide administration in Type 2 diabetes

被引：3
|
作者：
Smits, M. M. [1 ]
Tonneijck, L. [1 ]
Muskiet, M. H. A. [1 ]
Diamant, M. [1 ]
Kramer, M. H. H. [1 ]
Cahen, D. L. [2 ]
van Raalte, D. H. [1 ]
机构：
[1] Vrije Univ Amsterdam Med Ctr, Diabet Ctr, Dept Internal Med, Amsterdam, Netherlands
[2] Erasmus Univ, Dept Gastroenterol & Hepatol, Med Ctr, Rotterdam, Netherlands
来源：
DIABETIC MEDICINE | 2017年 / 34卷 / 04期
关键词：
SECRETION; LIPASE;
D O I：
10.1111/dme.13160
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：591 / 592
页数：2
相关论文
共 50 条
  • [31] Glucagon-like peptide-1 therapy for youth with type 2 diabetes
    Cho, Young Min
    JOURNAL OF DIABETES INVESTIGATION, 2023, 14 (03) : 362 - 363
  • [32] MEDICATION USE AND TREATMENT PATTERNS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES MELLITUS
    Johnston, S. S.
    Nguyen, H.
    Felber, E.
    Cappell, K.
    Nelson, J.
    Chu, B. C.
    Kalsekar, I
    VALUE IN HEALTH, 2014, 17 (03) : A261 - A262
  • [33] Advances in Type 2 Diabetes: Focus on Basal Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy
    Shubrook, Jay H.
    JOURNAL OF FAMILY PRACTICE, 2018, 67 (08): : S49 - S54
  • [34] Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study
    Lassen, Mats C. H.
    Johansen, Niklas Dyrby
    Modin, Daniel
    Catarig, Andrei-Mircea
    Vistisen, Bodil Kjeldgaard
    Amadid, Hanan
    Zimmermann, Esther
    Gislason, Gunnar
    Biering-Sorensen, Tor
    DIABETES OBESITY & METABOLISM, 2024,
  • [35] Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management
    Kyriakidou, Artemis
    Koufakis, Theocharis
    Goulis, Dimitrios G.
    Vasilopoulos, Yiannis
    Zebekakis, Pantelis
    Kotsa, Kalliopi
    CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (08) : 1025 - 1034
  • [36] Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials to the Type 2 Diabetes Population in China
    Cai, Xiaoling
    Zhang, Lin
    Wu, Haiya
    Huo, Li
    Ma, Xiao
    Cao, Haijun
    Ji, Linong
    DIABETES, 2020, 69
  • [37] Effectiveness of glucagon-like peptide-1 agonists in type 2 diabetes
    Pavlicek, Vojtech
    DIABETOLOGIE, 2023, 19 (03): : 359 - 360
  • [38] Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
    Toft-Nielsen, MB
    Madsbad, S
    Holst, JJ
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (08): : 3853 - 3860
  • [39] Therapeutics Glucagon-like peptide-1 analogues for type 2 diabetes
    Wilding, John P. H.
    Hardy, Kevin
    BRITISH MEDICAL JOURNAL, 2011, 342 : 433 - 435
  • [40] Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes
    Edwards, C. M. B.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2013, 74 (04) : 198 - 201
12345